A London-based firm investing in venture capital and public equities in life sciences, focused on advanced therapies addressing high unmet medical and social needs.

4BIO Capital

4BIO Capital is an international venture capital firm focused solely on the advanced therapies sector. 

4BIO’s objective is to invest in, support, and grow early stage companies developing treatments in areas of high unmet medical need, with the ultimate goal of ensuring access to these potentially curative therapies for all patients. Specifically, it looks for viable, high-quality opportunities in cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome.

The 4BIO team comprises leading advanced therapy scientists and experienced life science investors who have collectively published over 250 scientific articles in prestigious academic journals including Nature, The Lancet, Cell, and the New England Journal of Medicine. 4BIO has both an unrivalled network within the advanced therapy sector and a unique understanding of the criteria that define a successful investment opportunity in this space.

For more information, please visit www.4biocapital.com


Congratulations to our portfolio company Vianautis on having appointed Steven Altschuler M.D. as Chairman.
 
Dr Altschuler is a renowned biotech company founder, director and board leader with proven experience in successfully leading and supporting companies focused on advanced therapies and drug delivery systems including Spark Therapeutics, Inc. (acquired by Roche in 2019 for $4.8 billion), Orchard Therapeutics (a 4BIO Capital portfolio company acquired by Kyowa Kirin Co., Ltd. in 2024 for $477.6 million), Lexeo Therapeutics and 89bio.

#AdvancedTherapies #Nanomedicines #DrugDelivery #VC #Chairman #Appointment

We are thrilled to announce that our portfolio company, Hornet Therapeutics, has emerged from stealth with the publication of significant new data published in the prestigious journal, Science Magazine.

The published data demonstrate the first ever small molecule drug, HTX-201, with the potential for treating Epstein-Barr Virus driven (EBV) diseases.

HTX-201 was exclusively in-licensed from Kyowa Kirin Co., Ltd. and Hornet now looks forward to progressing at speed into proof-of-concept trials in solid organ transplant populations. 

Read the full press release: https://lnkd.in/eChcme7k

Read the publication in Science: https://lnkd.in/gtGHPXgs

#publication #4BIO #AdvancedTherapies #CompanyLaunch

We want to thank all our partners and our portfolio companies Araris Biotech AG, Ascend  , Carisma Therapeutics, Code Biotherapeutics, Entact Bio, Hornet Therapeutics, LUCA Science Inc., Ray Therapeutics, Inc. and SparingVision for joining us at our 2023 AGM last week where we were able to provide an update on the fund’s progress as well as discuss industry trends including environmental sustainability and what’s next in the advanced therapies space.

Special mention goes to Rahul Parekh of 2150 and Patient Advocate Tamar Bresge for providing their valuable insights.

#VC #AdvancedTherapies #4BIOAGM #AGM #Biotech

We were privileged to host Masami Sakoi, the Vice-Minister of Health and Tadayuki Mizutani, Director of the Policy Planning Division for the Pharmaceutical Industry of Japan and delegates from Japan’s Ministry of Health, Labour and Welfare at our offices in London.
 
Discussions revolved around the value proposition of incubators and accelerators in the life sciences field, as well as the mechanisms through which early-stage ventures interact and collaborate with accelerators. 
The meeting served as a valuable platform for knowledge sharing and collaboration between 4BIO Capital and representatives from Japan, reinforcing the importance of international partnerships in advancing the global life sciences landscape.
 
#AdvancedTherapies #DrugDelivery #VC #collaboration

It was a busy day at Bio€quity Europe 2024 here in San Sabastián, meeting other attendees from across the industry and our Managing Partner, Dmitry 'Dima' Kuzmin participating in the ‘Scaling up Europe’s academic engine in cell and gene therapy’ R&D showcase.

#AdvancedTherapies #GeneTherapy #CellTherapy #VC #showcase #BioEquity #Conference BioCentury Inc. EBD Group

Join our Managing Partner, Andrew Kozlov, tomorrow as he participates in the ‘How to Strengthen the Vital Link to Your Investors in Uncertain Times’ panel at the Swiss Biotech Day 2024 in Basel alongside Alexandra Wollersheim, Partner, Transaction Advisory Services, Alira Health, Ajla Hrle, Head of Life Sciences, ATHOS KG and Sarah Holland, Chief Business Officer, Cureteq AG - a Partex Company.

This panel will focus on practical solutions to restore the vital link between investors and innovators, recognizing their mutual dependence for value creation.

We hope to see you there!

https://lnkd.in/gBn4ZUd

#AdvancedTherapies #GeneTherapy #CellTherapy #VC #PanelDiscussion #SwissBiotech #Conference

Viewport Meta

IPhone / Mobile Compatible

SSL by Default

Apple Mobile Web Clips Icon

HSTS

Content Delivery Network

Google Cloud

PayPal

Google Cloud CDN

Partner, General Counsel

Kieran Mudryy

Financial Controller

Edward McGill

Managing Partner, Co-Founder

Andrew Kozlov

Equity Analyst - Biotech

Anna Tokarenko

Managing Partner

Dmitry Kuzmin

Office Assistant

Eleanor Whate

Investment Analyst

Juliette Lee

Associate

Natalie Johnston

Paralegal and Compliance Assistant

Sophia Papageorgiou

Chief Operating Officer

Vasily Fedorin

Owen Smith

Principal

Yury Kukushkin

Venture Partner

Partner

Carisma Therapeutics is a biotech company that develops novel chimeric antigen receptor macrophage technology to treat solid tumors.

ADC Therapeutics develops antibody drug conjugates and non-antibody drug conjugate products.

Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer.

Autolus is a biopharmaceutical company focused on T-cell programming and manufacturing technology.

Orchard Therapeutics is a biotechnology company dedicated to assisting patients through innovative gene therapies.

Redpin Therapeutics is a preclinical stage gene therapy company that develops chemogenetics platform designed for nervous system diseases.

The University of Chicago Booth School of Business Alumni Founded Companies

United Kingdom Venture Capital Investors

Early Stage Venture Investors (Top 10K)

England Venture Capital Investors

4BIO Ventures is a London-based firm investing in venture capital and public equities in life sciences. They are focused on advanced therapies addressing high unmet medical and social needs.

4BIO Capital Partners is an emerging asset manager focusing on private equity and venture capital in high growth and high return segments of biotech - biologics, gene and cell therapy and bioinformatics.

4Bio Ventures II

London

England

United Kingdom

Europe

4BIO Capital Portfolio Company Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy

4BIO Capital Portfolio Company Ascend Acquires Florida-Based GMP Manufacturing Capacity

4BIO Capital Strengthens Advisory Board and Investment Team

Development Bank of Japan invests in 4BIO Capital’s Ventures III fund

Development Bank of Japan invests in 4BIO Capital's

United States

North America

Singapore

Asia

India

Indonesia

HTML5

Microsoft Outlook

Vimeo

Google Compute Engine

GreenSock Animation Platform

Google Tag Manager

Google Analytics

Google Fonts

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Jul 18, 2024 6:48 AM	493d0adc
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Jul 18, 2024 8:13 PM	eebb857c
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	de8ae5da
crunchbase profile	general	Nov 25, 2024 11:00 AM	227f9d25
li profile	general	Jul 18, 2024 6:48 AM	d9b9ddd1
translate crunchbase fundingrounds	general	Nov 25, 2024 2:11 PM	ef311bb5
peers	general	Jul 18, 2024 6:48 AM	277812de
news basic	general	Jul 18, 2024 6:48 AM	766bb0f2
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:4BIOCAPITAL

4BIO Capital